NF 340 - CAS 202982-98-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C37H26N4Na4O15S4
Molecular Weight:
986.84
COA:
Inquire
Targets:
P2Y Receptor
Description:
NF 340 is a selective P2Y11 antagonist. It shows competitive antagonism against ATPγS with pIC50 values of 6.43 and 7.14 in Ca2+ and cAMP assays respectively.
Purity:
≥95% by HPLC
Synonyms:
NF 340; NF-340; NF340; 4,4'-(Carbonylbis(imino-3,1-(4-methyl-phenylene)carbonylimino))bis(naphthalene-2,6-disulfonic acid) tetrasodium salt
MSDS:
Inquire
InChIKey:
SJMHXBFWMZYDBY-UHFFFAOYSA-J
InChI:
InChI=1S/C37H30N4O15S4.4Na/c1-19-3-5-23(35(42)38-33-17-27(59(51,52)53)11-21-7-9-25(15-29(21)33)57(45,46)47)13-31(19)40-37(44)41-32-14-24(6-4-20(32)2)36(43)39-34-18-28(60(54,55)56)12-22-8-10-26(16-30(22)34)58(48,49)50;;;;/h3-18H,1-2H3,(H,38,42)(H,39,43)(H2,40,41,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56);;;;/q;4*+1/p-4
Canonical SMILES:
CC1=C(C=C(C=C1)C(=O)NC2=C3C=C(C=CC3=CC(=C2)S(=O)(=O)[O-])S(=O)(=O)[O-])NC(=O)NC4=C(C=CC(=C4)C(=O)NC5=C6C=C(C=CC6=CC(=C5)S(=O)(=O)[O-])S(=O)(=O)[O-])C.[Na+].[Na+].[Na+].[Na+]
1.Carcinoma-specific expression of P2Y11 receptor and its contribution in ATP-induced purinergic signalling and cell migration in human hepatocellular carcinoma cells.
Khalid M;Brisson L;Tariq M;Hao Y;Guibon R;Fromont G;Mortadza SAS;Mousawi F;Manzoor S;Roger S;Jiang LH Oncotarget. 2017 Jun 6;8(23):37278-37290. doi: 10.18632/oncotarget.16191.
Extracellular ATP-induced Ca2+ signalling is critical in regulating diverse physiological and disease processes. Emerging evidence suggests high concentrations of extracellular ATP in tumour tissues. In this study, we examined the P2 receptor for ATP-induced Ca2+ signalling in human hepatocellular carcinoma (HCC) cells. Fura-2-based measurements of the intracellular Ca2+ concentration ([Ca2+]i) showed that extracellular ATP induced an increase in the [Ca2+]i in human HCC Huh-7 and HepG2 cells. NF546, a P2Y11 receptor agonist was equally effective in inducing an increase in the [Ca2+]i. In contrast, agonists for the P2X receptors (αβmeATP and BzATP), P2Y1 receptor (MRS2365) or P2Y2 receptor (MRS2768) were ineffective. In addition, ATP/NF546-induced increases in the [Ca2+]i were strongly inhibited by treatment with NF340, a P2Y11 receptor antagonist. Immunofluorescent confocal imaging and western blotting analysis consistently demonstrated the P2Y11 receptor expression in Huh-7 and HepG2 cells. Transfection with P2Y11-specific siRNA attenuated the P2Y11 receptor protein expression level and also reduced NF546-induced increase in the [Ca2+]i. Importantly, immunohistochemistry revealed that the P2Y11 receptor was expressed at very high level in human HCC tissues and, by contrast, it was barely detected in normal liver tissues.
2.Participation of peripheral P2Y1, P2Y6 and P2Y11 receptors in formalin-induced inflammatory pain in rats.
Barragán-Iglesias P;Mendoza-Garcés L;Pineda-Farias JB;Solano-Olivares V;Rodríguez-Silverio J;Flores-Murrieta FJ;Granados-Soto V;Rocha-González HI Pharmacol Biochem Behav. 2015 Jan;128:23-32. doi: 10.1016/j.pbb.2014.11.001. Epub 2014 Nov 6.
Metabotropic P2Y receptors subfamily consists of eight functional mammalian receptors. Specifically, P2Y1, P2Y6 and P2Y11 receptors have been described in the sensory nervous system, but their participation, at peripheral level, in behavioral pain models is scarcely understood. This study assessed the role of peripheral P2Y1, P2Y6 and P2Y11 receptors in formalin-induced inflammatory pain. Ipsilateral, but not contralateral peripheral pre-treatment with the endogenous P2Y1 (ADP, 100-1000nmol/paw), P2Y6 (UDP, 180-300nmol/paw) and P2Y11 (ATP, 100-1000nmol/paw), or selective P2Y1 (MRS2365, 0.1-10nmol/paw), P2Y6 (PSB0474, 0.1-0.10pmol/paw) and P2Y11 (NF546, 0.3-3nmol/paw) receptor agonists increased 0.5% formalin-induced flinching behavior. Concordantly, peripheral pre-treatment with the selective P2Y1 (MRS2500, 0.01-10pmol/paw), P2Y6 (MRS2578, 3-30nmol/paw) and P2Y11 (NF340, 1-10nmol/paw) receptor antagonists significantly decreased 1% formalin-induced flinching behavior. Furthermore, the pronociceptive effect of ADP (100nmol/paw) or MRS2365 (10nmol/paw), UDP (300nmol/paw) or PSB0474 (10pmol/paw) and ATP (1000nmol/paw) or NF546 (3nmol/paw) was blocked by the selective P2Y1 (MRS2500, 0.01nmol/paw), P2Y6 (MRS2578, 3nmol/paw), and P2Y11 (NF340, 1nmol/paw) receptor antagonists, respectively.
3.Role of spinal P2Y6 and P2Y11 receptors in neuropathic pain in rats: possible involvement of glial cells.
Barragán-Iglesias P;Pineda-Farias JB;Cervantes-Durán C;Bravo-Hernández M;Rocha-González HI;Murbartián J;Granados-Soto V Mol Pain. 2014 May 20;10:29. doi: 10.1186/1744-8069-10-29.
BACKGROUND: ;The participation of spinal P2X receptors in neuropathic pain is well recognized. However, the role of P2Y receptors has been less studied. The purpose of this study was to investigate the contribution of spinal P2Y6,11 receptors following peripheral nerve damage induced by spinal nerve ligation. In addition, we determined the expression of P2Y6,11 receptors in the dorsal spinal cord in presence of the selective P2Y6,11 receptors antagonists. Furthermore, we evaluated the participation of spinal microglia and astrocytes in the pronociceptive role of P2Y6,11 receptors.;RESULTS: ;Spinal administration of the selective P2Y6 (MRS2578, 10-100 μM) and P2Y11 (NF340, 0.3-30 μM) receptor antagonists reduced tactile allodynia in spinal nerve ligated rats. Nerve injury increased the expression of P2Y6,11 receptors at 7, 14 and 21 days after injury. Furthermore, intrathecal administration of MRS2578 (100 μM/day) and NF340 (30 μM/day) for 3 days significantly reduced spinal nerve injury-induced increase in P2Y6,11 receptors expression, respectively. Spinal treatment (on day 14 after injury) with minocycline (100 μg/day) or fluorocitrate (1 nmol/day) for 7 days reduced tactile allodynia and spinal nerve injury-induced up-regulation in Iba-1 and GFAP, respectively.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related P2Y Receptor Products


CAS 1006028-37-0 NF 546

NF 546
(CAS: 1006028-37-0)

NF 546 is a P2Y11 agonist with pEC50 value of 6.27. It can stimulate release of interleukin-8 from human monocyte-derived dendritic cells.

CAS 129-46-4 Suramin Sodium

Suramin Sodium
(CAS: 129-46-4)

The sodium salt of Suramin which is a P2 purinergic antagonist and has been also found to have the effect in blocking the G protein binds to GPCRs so that it wa...

CAS 163706-06-7 Cangrelor

Cangrelor
(CAS: 163706-06-7)

Cangrelor, an adenylic acid derivative, has been found to be a P2Y12 inhibitor that could be effective in some coronary artery diseases. It is under Phase I tri...

CAS 211427-08-6 Diquafosol tetrasodium

Diquafosol tetrasodium
(CAS: 211427-08-6)

Diquafosol tetrasodium, also referred to Diquas, is aP2Y2receptor agonist that is targeted to treat dry eye disease through rehydration of the ocular surface.

CAS 1047980-83-5 MRS 2768 tetrasodium salt

MRS 2768 tetrasodium salt
(CAS: 1047980-83-5)

MRS 2768 tetrasodium salt is a selective P2Y2 agonist (EC50 = 1.89 μM), with no affinity for human P2Y4 or P2Y6 receptors.

CAS 1343364-54-4 αβ-methylene ATP

αβ-methylene ATP
(CAS: 1343364-54-4)

αβ-methylene ATP, a phosphonic analog of ATP, is an agonist of P2X purinoceptors P2X1 and P2X3 (EC50 = ~1 µM) and is ~1,000-fold less potent at P2X2, P2X recept...

CAS 1266569-94-1 UTPγS trisodium salt

UTPγS trisodium salt
(CAS: 1266569-94-1)

UTPγS trisodium salt is a selective P2Y2 and P2Y4 receptor agonist.

CAS 1279829-64-9 SAR 216471 hydrochloride

SAR 216471 hydrochloride
(CAS: 1279829-64-9)

SAR 216471 hydrochloride is a potent and reversible P2Y12 antagonist (IC50 = 17 nM), displaying antiplatelet and antithrombotic activity in vivo.

Chemical Structure

CAS 202982-98-7 NF 340

Quick Inquiry

Verification code

Featured Items